A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.

Conditions

Mantle Cell Lymphoma
Non-Hodgkin's Lymphoma

Interventions

DRUG: Lenalidomide
OTHER: Placebo

Sponsor

Celgene